FAU Enters into Licensing Agreement with Neuro Pharmalogics, Inc. for Therapies to Treat Rare Neurological Diseases
Tuesday, November 29, 2016 - 14:31
in Health & Medicine
The portfolio of patents focuses on the PKG (protein kinase G) pathway, which plays a pivotal role in several neurological conditions by controlling cortical spreading depolarization. Research at FAU has found that neurological diseases, including hemiplegic migraine - a severe type of migraine that can affect patients up to 15 times a month and can paralyze half the body - as well as neural trauma (traumatic brain injury and spinal shock), stroke, and epileptic conditions can be targeted through the PKG signaling pathway.